The present study demonstrates the action of the hypoglycaemic drugs repaglinide and glibenclamide in cultured newborn rat islet cells and mouse flTC3 cells. In cell-attached membrane patches of newborn rat islet cells repaglinide (10 nmol/ 1) and glibenclamide (20 nmol/1) decrease the open probability of single ATP-sensitive K + -channels to approximately 10 % of the activity prior to addition of the drugs in short-term experiments (< 5 min). The influence of repaglinide and glibenclamide on the ATP-sensitive K + current was studied using the whole-cell patch clamp configuration. A half-maximal steady-state inhibition of the ATP-sensitive K + currents is observed at 89 pmol/1 repaglinide and at 47 pmol/1 glibenclamide in whole-cell experiments of longer duration (30 min). Applying digital Ca 2 + imaging on single flTC3 cells we found that repaglinide and glibenclamide induced a concentration-dependent increase in intracellular free Ca 2+ concentration ([Ca 2 +]i) with a half-maximal effect at 0.5 nmol/1 for both drugs in long-term experiments (30 min). The rise in [Ca 2+ ]i results from Ca 2+ entry through voltage-dependent L-type Ca 2+ -channels since it is inhibited by verapamil (10 ~mol/1). The effect of repaglinide and glibenclamide is partly reversible (= 80 %). [Diabetologia (1995[Diabetologia ( ) 38: 1025[Diabetologia ( -1032 
voltage-dependent Ca 2 + -channels. Ca 2 + then enters the cell and initiates insulin secretion [4] . Recently, it has become evident that sulphonylureas also promote insulin secretion by an interaction with the secretory machinery [5] .
Sulphonylurea treatment can result in a gradual loss of glycaemic control with time, a phenomenon called secondary failure [1, 6] . Furthermore, sulphonylurea treatment does not restore the first phase insulin secretion which is virtually absent in patients with NIDDM [7, 8] . In an attempt to circumvent these problems, and to improve blood glucose control, several new hypoglycaemic drugs have been developed. One such drug is repaglinide, a benzoic acid derivate (Fig. 1) , which has been reported to enhance insulin secretion, to have a short plasma halflife and which is secreted predominantly via the bile [9] . Repaglinide has an insulinotropic effect in humans [9] , although its mechanism of action in the pancreatic beta-cell remains to be established. There- fore, we investigated the effects of repaglinide on cultured newborn rat islet cells and fiTC3 cells using patch-clamp techniques and digital Ca 2+ imaging. The results were compared with the sulphonylurea glibenclamide and partly presented previously [10] .
Materials and methods
Chemicals. Fura-2 acetoxymethyl ester (Fura-2/AM) and fura-~2 pentapotassium salt were supplied by Molecular Probes (Eugene, Ore. USA). EGTA was obtained from Fluka (Buchs, Switzerland). Repaglinide was synthesized at Dr. Karl Thomae GmbH (Biberach an der Riss, Germany). All other chemicals were obtained from Sigma Chemical (St. Louis, Mo., USA).
Cell culture. Islet cells were isolated from newborn rats and cultured for up to 3 months, as described previously [11] . The newborn rat islet cells were used for the electrophysiological recordings whereas the flTC3 cell line, derived from a transgenic mouse insulinoma [12] , was used for all Ca 2 + measurements. The latter cell line was used because we were unable to make the newborn rat cells attach to glass coverslips, necessary for measurements of [Ca 2+ ]i. The fiTC3 cells were cultured at 37 ~ in Dulbecco's modified Eagle medium containing 1000 mg/1 D-glucose, 10 % heat-inactivated fetal calf serum, penicillin (50 U/ml), streptomycin (0.05 mg/ml), 2 retool/1 L-glutamine (Gibco, Roskilde, Denmark) and incubated in humidified 5 % CO 2 in 95 % air. Cells were passaged once each week and media were changed twice a week. All experiments were performed with cells from passage 30-45. For cell-attached patch-clamp experiments the pipette solution contained (in mmol/1): 6 Na + , 155 K + , 2 Ca 2+ , 1 Mg 2+ , 137 C1-, 10 EGTA, 0.3 ATP, 5 HEPES, pH 7.2: the extracellular solution contained (in mmol/1): 140 Na + , 4K + , 2 Ca 2+ , 1 Mg 2+ , 150 C1-, 10 HEPES, pH 7.3. In cell-attached single-channel experiments the recordings were performed at the resting membrane potential of the cell and the applied voltage was 0 mV. In whole-cell experiments the same solutions were used as described above. The membrane potential was held at -70 mV and hyper-and depolarizing voltage pulses of 10 mV amplitude and 250 ms duration were applied alternately every 1.5 s [13] . At the applied membrane potentials, voltage dependent currents, i.e., the Ca 2+ inward currents and the delayed K § outward current are not induced and therefore most of the current is flowing through K + ATp-channels. In addition, activation of Ca 2 + -dependent K + -channels was prevented by including EGTA in the pipette solution [14, 15] . Solutions were applied by gravity feed from a series of parallel pipes. Solution changes around the cell were complete within 5 s as measured by monitoring the membrane potential during a step in extracellular K + concentration from 4 to 45 retool/1. The experiments were performed at room temperature.
Measurements of [Ca 2+
]i. Images of [Ca 2+ ]i in single fiTC3 cells were obtained by means of a fluorescence microscope (Zeiss Axiovert 135, Oberkochen, Germany) with a Xenon lamp (75 W), a CCD camera (Dage-MTI, Michigan City, Ind., USA) with an intensifier (Genesis, Dage-MTI) and a digital image processing system (Universal imaging, West Chester, Pa., USA). The cells were loaded with 3 [xmol/1 fura-2/AM for 40 min at 37~ Before the experiment the cells were washed twice with extracelhilar solution (see previous section) and placed in a perfusion chamber which allows for a continuous flow of control or test solution at rates between 0.1-2 ml/min. Images were obtained by an oil-immersion UV permeable objective (Zeiss Achrostigmat 40 x, 1.30 numerical aperture) and transferred to a video tape recorder (Umatic SR VO 9600, Sony, Copenhagen, Denmark). The images were obtained by averaging eight frames using a sample rate between 0.2--0.5 Hz. The data were obtained by averaging the pixel grey values inside a 4 x 4-Fro window placed in the centre of the cells.
The free intracellular Ca 2 + concentrations were calculated from the measurements of the ratio of fluorescence intensities according to the equation [16] : [Ca~+]i=K d 9 [(R-Rmin)/ (Rmax-R)] " (S f2/Sb2). Calibrations of intracellular fura-2 signals were done by adding ionomycin to a final concentration of 1 ~tmol/1 in order to equilibrate Ca 2 + across the plasma membrane. The grey values obtained for Rm, x amounted in average to 241. Rmi n and the proportionality constant (Sf2/Sb2) were obtained from a high K + -medium with fura-2 pentapotassium salt and 10 mmol/1 EGTA and amounted to 27 and 9.8, respectively. A value for the apparent dissociation constant (Kd) for Ca 2+ binding to fura-2 of 224 nmol/1 was used [16] . All experiments were performed at room temperature (20-22 ~ Measurements of electrical activity. Single-channel and wholecell ion currents were recorded using an EPC-9 patch-clamp The currents are displayed as downward deflections indicating that the currents are inward. This is solely due to the high K + concentration of the intracellular solution in the pipette and under physiological conditions the currents will be outwardly directed tending to repolarize the beta-cell. The experiment is performed at 22-24 ~
Statistical analysis
All data are expressed as means + SEM for n tested cells.
Curves were fitted to the data by a non-linear least-squares method using the computer program Statgraphics from STST Inc. (Rockville, Md., USA). In order to measure the inhibitory effect of repaglinide and glibenclamide on the mean current amplitude a curve was fitted to the data points by the following equation, which is a simplified version of the Hill equation assuming a cooperativity of one:
where I is the change in current amplitude, I c is the maximum change in current amplitude in the absence of drug, [ICs0 ] is concentration of repaglinide or glibenclamide giving half-maximal inhibition and S is the concentration of the inhibitor. In these experiments differences in cell size were not corrected for, as we did not find any correlation between cell size and the maximum current amplitudes. For measurements of concentration-response curves the data were fitted by means of the Michaelis-Menten equation: 
Results
Effects of glucose and repaglinide on K + ATp-channel activity. Figure 2 shows the effect of glucose and repaglinide on individual K + ATe-channels in a cell-attached patch of membrane of cultured beta-cells from neonatal rats. From observations of channel activity over a range of voltages we found a reversal potential of -70 to -80 mV and a maximum slope conductance of approximately 70 pS in symmetrical K + solutions. In most experiments, glucose alone (16.7 mmol/1) totally blocked the K+Axwchannels within approx. 8 min. This effect is reversible since reducing bath glucose to 0 mmol/1 results in the return of channel activity within 5-10 min. Subsequent addition of repaglinide (10 nmol/1) inhibited channel activity approximately 90 % within 1-4 min. The effect of repaglinide was not reversible within 30 min of washout. Similar results were obtained with glibenclamide, although 20 nmol/1 was required in order to obtain 90 % inhibition of channel activity. The effects of repaglinide and glibenclamide are specific for K + azp-channels, since the drugs did not affect the Ca 2 + -sensitive K + -channels or the smaller ( = 15 pS) K + -channels also present in the beta-cells (data not shown). All experiments examining the effects of repaglinide or glibenclamide were performed in a glucose-free medium in order to avoid contributions from glucose induced changes on K + ATe-channel activity and [Ca 2+ ]iEffect of repaglinide and glibenclamide on A TP-sensitive K + whole-cell current. At low repaglinide and glibenclamide concentrations it becomes difficult to separate drug effect from spontaneous rundown of K + A~-channels. Thus, in order to establish the doseresponse relationship for repaglinide and glibenclamide we used a different whole-cell protocol [13] . The beta-cells were preincubated for 30 min with different concentrations of the drugs and the current was recorded at a holding potential of -70 mV applying hyper-and depolarizing pulses of 10 mV. Figure  3A illustrates the current responses in the absence of drugs and in the presence of i nmol/1 repaglinide. After patch rupture and dialysis of the cell with a pipette solution of low ATP concentration (0.3 mmol/1) the whole-cell K + current gradually increased to a maximal value of approximately 500 pA in the control and approximately 50 pA in the presence of 1 nmol/1 repaglinide. We found that an equilibrium state of the blocking effect of all tested drug concentrations was achieved after 30 min of incubation. Exposure of the cells to different repaglinide and glibenclamide concentrations caused a concentration-dependent decrease of the maximal current amplitude. By fitting a curve to the data (Eq. I) an ICs0-value of 89 + 13 pmol/1 for repaglinide and 47 + 4 pmol/1 for glibenclamide was calculated (Fig. 3B,C) . 
Effects of repaglinide and glibenclamide on [Ca

Reversibility of repaglinide and glibenclamide.
We have investigated the reversibility of repaglinide and glibenclamide on the ATP-sensitive whole-cell K +-current in newborn rat islet cells. After pretreatment with 100 nmol/1 of each drug for 30 min the cells were washed with drug free medium for variable periods of time before a whole cell experiment was performed. After 250 min of washing we found approximately 80 % recovery of the maximal ATP-sensitive K + current in cells pretreated with 100 nmol/1 repaglinide (Fig. 6A) . Similar results were obtained with glibenclamide (data not shown). We have also exam- 
Discussion
The present study demonstrates that the hypoglycaemic drugs repaglinied and glibenclamide block the K § ATp-channels found in pancreatic beta-cells, thereby causing Ca 2 § influx through voltage-dependent Ltype Ca 2+ -channels and a subsequent increase in
[ Caz+ ]i-The K + Are-channels found in the present study are similar to those previously described in beta-cells from newborn rats [17] and in other types of beta-cells [4, 18] . Repaglinide and glibenclamide caused a dose-dependent inhibition of the K + ATechannels, which constitute the resting conductance of the beta-cell [4, 18] . Thus, 89 pmol/1 repaglinide blocked the ATP-sensitive K + -currents half-maximally whereas glibenclamide inhibited the currents half-maximally at 47 pmol/1. By comparison, Sturgess et al. [19] found that 27 nmol/1 glibenclamide was needed in order to block the ATP-sensitive K + -current in CRI-G1 insulinoma cells half-maximally. In mouse pancreatic fi-cells 0.4--0.6 nmol/1 glibenclamide (free concentrations) was required in order to inhibit the ATP-sensitive K + -current half-maximally [20, 21] . However, in RIN cells 60 pmol/1 glibenclamide was half-maximally effective on 86Rb+ effiux which reflects the activity of the K7 ~ ATe-channels [22] . We have shown the presence of functional K + Arechannels in flTC3 cells which were sensitive to inhibition by repaglinide and glibenclamide (data not shown). Thus, the observed rise in [Ca 2+ ]i in re- sponse to repaglinide or glibenclamide is due to inhibition of the K + Azp-channels, thereby causing membrane depolarization and Ca 2 + influx. The extracellular source of Ca 2 + is supported by the observation that verapamil, a L-type Ca 2 + channel blocker, prevents the rise in [Ca 2+ ]iRepaglinide and glibenclamide were about six and tenfold more potent in the electrophysiological experiments than in measurements of [Ca 2+ ]i (ks = 0.5 nmol/1 for both drugs). Patch-clamp experiments have revealed that complete closure of the K + A~-channels is required for the pancreatic beta-cell to be depolarized beyond the threshold for the generation of Ca2+-dependent action potentials [4] . Against this background it is clear that higher concentrations of repaglinide and glibenclamide are needed to cause a half-maximal increase in [Ca 2+ ]i. However, we acknowledge that the dose-response relationships on the K § Azp-currents and [Ca 2 + ]i were determined on two different beta-cell types. Preliminary results on ~TC3 cells have shown that the concentrations of repaglinide and glibenclamide causing half-maximal inhibition of the ATP-sensitive K + whole-cell current were approximately 100 pmol/1 which is nearly identical with those obtained in the present study on newborn rat islet cells. Thus, the difference in the dose-response relationships for repaglinide and glibenclamide determined in the present study is likely to reflect true differences in potency and is probably not due to the different cell types used. Our data on the potency of repaglinide and glibenclamide to cause an increase in [Ca 2+ ]i compare favourably with the potency of glibenclamide to stimulate insulin release in mouse pancreatic islets (ECs0 = 0.5 nmol/1) [21] .
Recently, it was demonstrated that the undissociated forms of glibenclamide and related compounds are the active forms for inhibition of the ATP-sensitive K + -currents and that the drugs probably gain access to their binding sites from the lipid phase of the beta-cell membrane [23] . In addition, an internalization of glibenclamide in rat islet cells occurs to a rather large extent where it preferentially associates with insulin secretory granules [24] . Thus, the rate of Time (min) Fig.ll (A, B) . Reversibility of repaglinide on the ATP-sensitive K + current and [Ca 2+ ]i. A Cells were pretreated with 100 nmol/1 repaglinide for 30 min and then washed for variable periods of time in drug-free medium before a whole-ceil experiment was performed. The ordinate shows the maximal whole-cell current in pA. The solid line was obtained by fitting the data points (n = 51) to the equation described in text. The dashed line represents the average maximal whole-cell current in control experiments (575 + 33 pA, n = 54). B Ca 2 + response in a/3TC3 cell after exposure to a maximally stimulating concentration of repaglinide (100 nmol/1). The cell was washed with bath solution containing 10 mg/ml albumin. Subsequent addition of repaglinide (100 nmol/1) took place after 57 min. The tracing is representative of nine experiments entry and the capacity of the cell will influence the access of the drug to its binding site. It seems likely that much larger amounts of drug accumulate in the cell than are needed to occupy all of the sulphonylurea receptors [25] . If we assume that internalization and accumulation of repaglinide also occurs, this might explain the kinetics of the onset of closure of the K + AT~,-channels and increase in [Ca 2 + ]i observed in the present study. Thus, with submaximal concentrations, the time course of entry and accumulation of repaglinide and glibenclamide in the cell will influence the onset and time course of channel closure and the subsequent increase in [Ca 2+ ]i. However, with maximal concentrations, repaglinide and glibenclamide will accumulate in the cell much more rapidly and occupy all binding sites, thereby inducing a more rapid rise in [Ca 2+ ]i subsequent to channel closure. The ability of repaglinide and glibenclamide to accumulate in the cell could also explain the slow reversibility on the ATP-sensitive K § -current and [ ca2 + ]i.
In conclusion, the new non-sulphonylurea-based hypoglycaemic agent repaglinide, a benzoic acid derivate, is equipotent with glibenclamide, a second generation sulphonylurea with respect to inhibition of beta-cell ATP-sensitive K + currents and stimulation of an increase in [Ca 2+ ]i. The close structural relationship between repaglinide and meglitinide, another hypoglycaemic drug which does not contain the sulphonylurea moiety, supports the observation first made by ZOnkler et al. [20] that the the sulphonylurea group is not necessary for inhibiting K + aTI'-channel activity and thus stimulating insulin secretion from the pancreatic beta-cell. It will be interesting to determine whether the non-sulphonylureas such as repaglinide and meglitinide share all properties of the sulphonylureas or if the sulphonylurea part of the molecules confers some distinct biological action.
